Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 11
Phase 21

Trial Status

Completed2

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT02437253Phase 1/2Completed
Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI
Mucopolysaccharidosis Type IMucopolysaccharidosis Type IIMucopolysaccharidosis Type VI
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Paul Orchard, MD

Masonic Cancer Center, University of Minnesota

Moderately Similar
9 trials

Shared therapeutic areas:

Mucopolysaccharidosis VIMucopolysaccharidosis IMucopolysaccharidosis II+1 more
Similarity Score30%

Chester B. Whitley, M.D., Ph.D.

University of Minnesota

Related
1 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis IIMucopolysaccharidosis VI

Worked with same sponsors:

National Center for Advancing Translational Sciences (NCATS)National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)+2 more
Similarity Score23%

Ashley Schneider

University of Minnesota

Related
1 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis IIMucopolysaccharidosis VI

Worked with same sponsors:

National Center for Advancing Translational Sciences (NCATS)National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)+2 more
Similarity Score23%

Paul Harmatz, M.D.

Oakland Children's Hospital

Related
1 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis IIMucopolysaccharidosis VI

Worked with same sponsors:

National Center for Advancing Translational Sciences (NCATS)National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)+2 more
Similarity Score23%

K. Scott Baker

Fairview University Medical Center

Related
3 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis VI
Similarity Score15%

Mitchell S Cairo, MD

New York Medical College

Related
13 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis VI

Worked with same sponsors:

UCSF Benioff Children's Hospital Oakland
Similarity Score15%

Melissa Wasserstein, MD

Albert Einstein College of Medicine

Related
2 trials

Shared therapeutic areas:

Mucopolysaccharidosis IIMucopolysaccharidosis VI
Similarity Score15%

Patrice Rioux, MD PhD

ArmaGen, Inc

Related
3 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis II
Similarity Score15%

Celeste Decker, MD

BioMarin Pharmaceutical

Related
4 trials

Shared therapeutic areas:

Mucopolysaccharidosis VI
Similarity Score8%

Arndt Rolfs, Prof. Dr.

CENTOGENE GmbH Rostock

Related
4 trials

Shared therapeutic areas:

Mucopolysaccharidosis II
Similarity Score8%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT01521429PrincipalInvestigator

Longitudinal Study of Bone Disease in Children with Mucopolysaccharidoses (MPS) I, II, and VI

Mucopolysaccharidoses
Completed
NCT02437253Phase 1/2PrincipalInvestigator

Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

Mucopolysaccharidosis Type IMucopolysaccharidosis Type IIMucopolysaccharidosis Type VI
Completed

All 2 trials loaded